Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-up of brivaracetam adjunctive therapy in focal epilepsy
2019-001205-25Phase 3
- Sponsor
- UCB
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in Focal Onset Epilepsy, sponsored by UCB. Primary endpoint: Treatment-emergent adverse events.
02
Drugs
brivaracetam
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2019-001205-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001205-25.